Literature DB >> 15769862

Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells.

T Z Su1, M R Feng, M L Weber.   

Abstract

Pregabalin (PGB) is a novel drug under development for the treatment of epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. In this study, we investigated PGB transport in rats, mammalian cell lines, and Xenopus laevis oocytes. In contrast to gabapentin (GBP), PGB absorption in rats showed unique linear pharmacokinetics. PGB entered CHO and Caco-2 cells predominately via Na(+)-independent processes. Uptake of PGB was mutually exclusive with leucine, GBP and 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid, the substrates preferential for system L. The preloaded PGB in CHO cells was exchangeable with leucine, but at a lower exchange rate than that of leucine and GBP. Dixon plots showed competitive inhibition of leucine uptake by PGB, with a K(i) value very close to the K(m) value for PGB uptake (377 versus 363 microM). At an extracellular concentration of 300 microM, the intracellular PGB concentration in CHO cells reached 1.5- and 23-fold higher than that of GBP and leucine, respectively. In contrast, at clinically relevant concentrations, PGB seemed not to interact with GABA transport in GAT1, GAT2, and GAT3 cell lines, system y(+), b(0,+), B(0,+), and B(0) transport activities in Caco-2 and NBL-1 cells, and the b(0,+)-like transport activity in rBAT cRNA-injected X. laevis oocytes. Taken together, these results suggest that L-type transport is the major transport route for PGB and GBP uptake in mammalian cells. The differential affinity of PGB and GBP at L-type system leads to more concentrative accumulation of PGB than GBP, which may facilitate PGB transmembrane absorption in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769862     DOI: 10.1124/jpet.104.082255

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

2.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

Review 3.  Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.

Authors:  Cory Toth
Journal:  Ther Adv Drug Saf       Date:  2014-02

Review 4.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

5.  In vivo and in vitro evaluations of intestinal gabapentin absorption: effect of dose and inhibitors on carrier-mediated transport.

Authors:  Malte Selch Larsen; Sidsel Frølund; Martha Kampp Nøhr; Carsten Uhd Nielsen; Mats Garmer; Mads Kreilgaard; René Holm
Journal:  Pharm Res       Date:  2014-09-03       Impact factor: 4.200

6.  Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of ca(v)2.1 calcium channels.

Authors:  Mariano N Di Guilmi; Francisco J Urbano; Carlota Gonzalez Inchauspe; Osvaldo D Uchitel
Journal:  J Pharmacol Exp Ther       Date:  2010-12-22       Impact factor: 4.030

7.  Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.

Authors:  Jan Hendrich; Alexandra Tran Van Minh; Fay Heblich; Manuela Nieto-Rostro; Katrin Watschinger; Jörg Striessnig; Jack Wratten; Anthony Davies; Annette C Dolphin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

Review 8.  Pregabalin for neuropathic pain based on recent clinical trials.

Authors:  Brett R Stacey; Jon N Swift
Journal:  Curr Pain Headache Rep       Date:  2006-06

Review 9.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.

Authors:  Gerald W Zamponi; Joerg Striessnig; Alexandra Koschak; Annette C Dolphin
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 10.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.